Results of the largest biomarker study, namely the UK/ANZ DCIS randomized trial, demonstrated that increased recurrence risk, particularly the risk of in situ ipsilateral second breast event (SBE), was associated with overexpression of HER2 [19]. Here, ERBB2 is linked to ductal breast carcinoma in situ.